Trust Signals
Key Takeaways
- Tesamorelin is the only injectable peptide with FDA approval specifically for body composition, backed by Phase III RCT data showing meaningful visceral fat reduction in a defined population.
- BPC-157 has compelling animal-model data across dozens of studies but zero published Phase II or III human RCTs as of mid-2026, placing it firmly in the research category.
- CJC-1295 with DAC has a plasma half-life measured in days versus minutes for CJC-1295 without DAC, a pharmacokinetic difference that changes dosing frequency entirely.
- Lyophilized peptides reconstituted in bacteriostatic water are stable for roughly 28 to 30 days refrigerated; beyond that, degradation products are invisible to the eye.
- A COA showing greater than 98 percent HPLC purity and mass-spec identity confirmation from a named third-party lab is the minimum quality bar worth trusting.
What Are the Best Peptides Injections? (Direct Answer)
Table of Contents
- Evidence Ledger: Every Major Claim Graded
- The Best Peptides Injections, Ranked by Evidence
- Mechanism With Numbers: How These Peptides Actually Work
- What Most Pages Get Wrong About Peptide Injections
- Head-to-Head: Peptides vs. Their Real Alternatives
- Why Do Storage Rules Exist? The Chemistry Explained
- How to Read a Peptide COA and Product Label
- Dosing Reference Table
- FAQ
- Sources
- Disclaimers
Evidence Ledger: Every Major Claim Graded
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Tesamorelin reduces visceral fat in HIV lipodystrophy | Phase III human RCT (Falutz et al., NEJM 2007) | Positive, statistically significant | High |
| Sermorelin raises GH and IGF-1 in adults with GHD | Multiple human trials, FDA-approved indication | Positive | High (in GHD), Moderate (healthy adults) |
| Ipamorelin + CJC-1295 raise IGF-1 in healthy adults | Small human pharmacokinetic studies, clinical practice data | Positive for IGF-1 | Moderate |
| BPC-157 accelerates tendon and gut healing | Rat and rodent models (multiple Sikiric group studies) | Positive in animals | Low (no human RCTs) |
| TB-500 promotes wound healing and angiogenesis | Animal models, limited small human data in wound care | Positive in animals | Low |
| Selank reduces anxiety in humans | Russian clinical trials (limited independent replication) | Positive in reported trials | Low to Moderate |
| Hexarelin raises GH acutely | Human pharmacology studies (small n) | Positive, tachyphylaxis noted | Moderate for acute GH release, Low for body composition outcomes |
| GH secretagogues carry cancer risk via IGF-1 | Epidemiological association, mechanistic plausibility | Theoretical risk, no causal RCT | Low (causation unproven) |
The Best Peptides Injections, Ranked by Evidence
1. Tesamorelin (Egrifta): FDA-approved, prescription only. The Falutz et al. 2007 NEJM trial (n = 412) showed statistically significant visceral adipose tissue reduction versus placebo over 26 weeks. The effect reverses after discontinuation. This is the only injectable peptide you can discuss with a physician using Phase III data.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →2. Sermorelin: FDA-approved for pediatric GHD, used off-label in adults. It is a 29-amino-acid GHRH analog. Plasma half-life is roughly 10 to 20 minutes. It is compounded widely; quality varies by pharmacy.
3. Ipamorelin: A selective ghrelin receptor agonist (GHSR-1a). Unlike GHRP-6, it does not significantly raise cortisol or prolactin at standard doses, which is why it is preferred clinically. It is nearly always dosed with a GHRH analog for synergistic GH pulse amplification.
4. CJC-1295 (without DAC): A modified GHRH analog with a plasma half-life of roughly 30 minutes, producing a physiologic GH pulse. The DAC version covalently binds albumin, extending half-life to several days but producing a sustained GH bleed rather than a pulse, which some clinicians consider less physiologic.
5. BPC-157: A 15-amino-acid synthetic peptide. Animal data from the Sikiric laboratory in Zagreb is extensive across gut injury, tendon repair, and neurological models. The FDA placed it on the list of peptides that may not be compounded for humans (2023 guidance). Evidence in humans is essentially absent as of mid-2026.
6. TB-500 (Thymosin Beta-4 fragment): Promotes actin sequestration, cell migration, and angiogenesis in animal models. Banned by WADA. Limited to animal and in-vitro data for athletic use.
7. Selank and Semax: Russian-developed neuropeptides with limited data available outside Eastern European literature. Selank is a tuftsin analog; Semax is an ACTH fragment. Anxiety and cognitive claims are based on trials not replicated in Western peer-reviewed journals with high methodological rigor.
Mechanism With Numbers: How These Peptides Actually Work
Growth hormone secretagogues operate via two distinct receptor pathways. GHRH analogs (sermorelin, tesamorelin, CJC-1295) bind the pituitary GHRH receptor (GHRHR), a G-protein coupled receptor that increases intracellular cAMP and stimulates GH synthesis and release. Ghrelin mimetics (ipamorelin, hexarelin, GHRP-6) bind GHSR-1a, a different GPCR, and amplify GH pulse amplitude through a separate intracellular pathway involving phospholipase C and protein kinase C.
Combining a GHRH analog with a ghrelin mimetic is synergistic because they act on different receptors and different intracellular cascades simultaneously. Studies using this combination report IGF-1 increases in the range of 30 to 50 percent above baseline in treated adults, though this range comes from small clinical series and off-label compounding experience rather than large RCTs.
BPC-157 is thought to work partly through upregulation of the nitric oxide system and modulation of VEGF (vascular endothelial growth factor) signaling, promoting angiogenesis and collagen synthesis. Rat tendon transection models from the Sikiric group show accelerated tendon healing at doses of roughly 10 mcg per kg. What this does not prove: that oral or subcutaneous bioavailability in humans is sufficient to replicate these concentrations at the injury site.
What Most Pages Get Wrong About Peptide Injections
Bioavailability is almost never discussed. Most peptide listicles describe mechanisms as if the peptide teleports to its target. Subcutaneous injection does not guarantee target-tissue concentration. Larger peptides are subject to proteolytic degradation in plasma and interstitial fluid. BPC-157's gastric origin means its animal data is largely from local (oral or intraperitoneal) administration. Subcutaneous human pharmacokinetic studies are sparse to nonexistent for most research peptides.
Purity sourcing is a real problem. "Research grade" peptide suppliers are not subject to FDA manufacturing oversight. Third-party testing by independent labs consistently finds a meaningful proportion of peptides sold online are misdosed, contaminated with residual solvents, or contain incorrect peptide sequences. A 2022 analysis published in Drug Testing and Analysis found that a substantial fraction of peptide samples purchased online did not match label claims. Never buy a peptide without a COA from a named independent lab.
The FDA 503B compounding restriction is not widely reported. In 2023, the FDA finalized guidance placing BPC-157, PT-141 (bremelanotide, now separately approved), and several other peptides on the list of bulk drug substances that may not be used in compounding. This affects what licensed compounding pharmacies can legally produce in the US.
Tachyphylaxis with GHRP-only protocols. Hexarelin and other GHRPs administered without a GHRH analog show rapid receptor desensitization (tachyphylaxis) within weeks. Many protocols fail to mention this, leading users to escalate dose rather than add a GHRH component.
Head-to-Head: Peptides vs. Their Real Alternatives
| Goal | Best Peptide Option | Real Alternative | Where Peptide Wins | Where Peptide Loses |
|---|---|---|---|---|
| Visceral fat reduction | Tesamorelin (Rx) | GLP-1 agonists (semaglutide) | Preserves lean mass better in some data | Effect reverses on stopping; semaglutide has broader body weight data |
| GH deficiency in adults | Sermorelin / CJC-1295 + ipamorelin | Recombinant human GH (somatropin) | Preserves pituitary feedback loop; lower cost | Less predictable IGF-1 normalization; no approved adult GHD indication for most |
| Tendon and soft tissue repair | BPC-157 | PRP injections, corticosteroids | Systemic rather than local delivery; animal data is extensive | No human RCT; legal gray area in the US; bioavailability unproven |
| Muscle hypertrophy | GH secretagogue stack | Testosterone (TRT), anabolic steroids | Safer hormonal profile; preserves HPTA | Effect size is dramatically smaller; evidence is far weaker |
| Wound healing | TB-500 | Standard wound care, growth factor dressings | Systemic action theoretically possible | WADA banned; no approved human indication; animal data only |
Why Do Storage Rules Exist? The Chemistry Explained
Lyophilized peptides are stable because freeze-drying removes water, which is the primary reactant in two main degradation pathways: hydrolysis and oxidation. Hydrolysis cleaves amide bonds in the peptide backbone, fragmenting the molecule. Oxidation attacks methionine and cysteine residues specifically, converting methionine sulfide to methionine sulfoxide and disrupting the three-dimensional conformation the peptide needs to bind its receptor.
Once you add bacteriostatic water (which contains benzyl alcohol as a preservative, not a stabilizer), the clock starts. Refrigeration at 2 to 8 degrees Celsius slows both hydrolysis (which is temperature-dependent, roughly following Arrhenius kinetics) and oxidation. Light exposure accelerates photooxidation via radical generation. This is why amber vials matter and why leaving a reconstituted vial on a countertop for days degrades it in ways you cannot see, smell, or taste.
The 28 to 30 day refrigerated use window is a conservative pharmaceutical standard based on sterility and chemical stability data for injectable preparations generally, not a number specific to each peptide. For some robust peptides the window may be longer; for cysteine-rich peptides it may be shorter. Without peptide-specific published stability data (which most research peptides lack), 28 days is the defensible default.
How to Read a Peptide COA and Product Label
A legitimate certificate of analysis must contain all of the following:
- Purity by HPLC: Look for a single major peak area greater than 98 percent. Multiple peaks indicate impurities or degradation products.
- Identity by mass spectrometry: The reported molecular weight should match the theoretical weight of the correct peptide to within 0.1 Da. This confirms you have the right molecule, not just a pure molecule.
- Endotoxin (LAL test): Injectable peptides should show endotoxin below 2 EU per kg per hour per FDA guidance for injectables. Many research peptide COAs omit this entirely, which is a red flag.
- Batch number: Must match the batch number on the vial. Generic COAs not tied to a specific batch are worthless.
- Testing laboratory name: Must be a named third-party lab, not the seller itself.
On the product label, the stated peptide amount (e.g., "5 mg per vial") should be verifiable against the COA weight. Reconstitution math: if you add 2 mL of bacteriostatic water to a 5 mg vial, you get a concentration of 2.5 mg per mL, or 2500 mcg per mL. A 250 mcg dose would then be 0.1 mL (10 units on an insulin syringe). Write this out before you draw up any dose.
Dosing Reference Table
| Peptide | Common Protocol Dose | Frequency | Route | Evidence Basis |
|---|---|---|---|---|
| Tesamorelin | 2 mg | Daily | Subcutaneous | FDA-approved label (Egrifta) |
| Sermorelin | 0.2 to 0.3 mg | Daily, before sleep | Subcutaneous | Compounding clinical practice; FDA-approved for pediatric GHD |
| Ipamorelin | 100 to 300 mcg | 1 to 3 times daily | Subcutaneous | Off-label clinical series |
| CJC-1295 (no DAC) | 100 to 200 mcg | Daily, with ipamorelin | Subcutaneous | Off-label clinical series |
| CJC-1295 (with DAC) | 1 to 2 mg | Once or twice weekly | Subcutaneous | Off-label; extended half-life pharmacokinetics |
| BPC-157 | 250 to 500 mcg | Daily | Subcutaneous or IM | Animal model extrapolation; no approved human dose |
| TB-500 | 2 to 2.5 mg | Twice weekly (loading), then weekly | Subcutaneous or IV | Animal model extrapolation; WADA prohibited |
All doses above are for research context. No dose table substitutes for individualized medical supervision.
FAQ
What are the best peptides injections for fat loss?
CJC-1295 and ipamorelin are the most commonly used combination for fat loss via growth hormone stimulation. Tesamorelin is the only peptide with FDA approval for visceral fat reduction, specifically in HIV-associated lipodystrophy, making it the highest-evidence option in this category.
What is the best peptide injection for muscle growth?
BPC-157 has solid animal data for tissue repair but limited human RCT data for muscle hypertrophy. Growth hormone secretagogues like ipamorelin combined with CJC-1295 are more commonly studied for lean mass. No injectable peptide has RCT-level evidence matching anabolic steroids for muscle growth.
How long does it take for peptide injections to work?
Onset depends on the peptide and outcome. GH secretagogues show measurable IGF-1 changes within weeks; body composition changes in studies appear over 6 to 26 weeks. BPC-157 tissue repair effects in animal models occur over days to weeks. Human timeline data is sparse.
Are peptide injections safe?
FDA-approved peptides (tesamorelin, sermorelin) have established safety profiles from clinical trials. Research peptides sourced from unregulated suppliers carry unknown impurity risks. Injection site reactions, water retention, and transient blood glucose changes are the most commonly reported effects with GH secretagogues.
What is the difference between BPC-157 and TB-500?
BPC-157 is a synthetic 15-amino-acid peptide derived from gastric juice, with animal data supporting gut and tendon healing. TB-500 is a synthetic fragment of thymosin beta-4, studied for angiogenesis and wound healing. Both lack human RCT data. They are often stacked, but no controlled human trial has evaluated the combination.
Do peptide injections require a prescription?
In the United States, FDA-approved peptides like tesamorelin and sermorelin require a prescription. Many peptides sold online are labeled "research use only" and exist in a legal gray area. The FDA has taken action against compounders selling certain peptides, including BPC-157, for human use.
What peptide injection is best for recovery?
BPC-157 has the most animal-model data for tendon, ligament, and gut recovery. TB-500 has some animal and limited human data for wound healing. Neither has passed a Phase III RCT for athletic recovery. Sermorelin and ipamorelin are used off-label for recovery via GH axis stimulation.
How do you store peptide injections?
Lyophilized (freeze-dried) peptides are stable at room temperature for months in sealed vials. Once reconstituted with bacteriostatic water, most peptides should be refrigerated at 2 to 8 degrees Celsius and used within 28 to 30 days. Heat, light, and repeated freeze-thaw cycles accelerate degradation via oxidation and hydrolysis.
What is the best dose for ipamorelin and CJC-1295?
Clinical and compounding protocols typically use ipamorelin at 100 to 300 mcg per injection and CJC-1295 (without DAC) at 100 to 200 mcg, dosed together before sleep. CJC-1295 with DAC has a longer half-life and is dosed less frequently. These are off-label doses; no standardized RCT protocol exists.
Can peptide injections cause cancer?
GH secretagogues raise IGF-1, which promotes cell proliferation. Chronically elevated IGF-1 is associated with increased cancer risk in epidemiological studies. No RCT has demonstrated a causal link between therapeutic GH secretagogue use and cancer, but the theoretical risk is real and is why these agents are contraindicated in people with active malignancies.
What does a peptide certificate of analysis tell you?
A legitimate COA from a third-party lab includes purity by HPLC (look for greater than 98 percent), identity confirmation by mass spectrometry, and ideally endotoxin testing. It should name the testing lab and batch number. A COA issued by the same company selling the product is not independent verification.
Sources
- Falutz J, Allas S, Blot K, et al. "Metabolic effects of a growth hormone-releasing factor in patients with HIV." New England Journal of Medicine. 2007;357(23):2359-2370.
- Sikiric P, Seiwerth S, Rucman R, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-1632.
- Walker RF. "Sermorelin: a better approach to management of adult-onset growth hormone insufficiency?" Clinical Interventions in Aging. 2006;1(4):307-308.
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
- Teichman SL, Neale A, Lawrence B, et al. "Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone." Journal of Clinical Endocrinology and Metabolism. 2006;91(3):799-805.
- Goldspink G, Yang SY. "The splicing of the IGF-I gene to yield different muscle growth factors." Advances in Genetics. 2004;52:23-49. (Background on IGF-1 and proliferation risk)
- Martello E, et al. "Fraudulent and counterfeit medicines and peptides: a review." Drug Testing and Analysis. 2022 (general reference for adulteration prevalence in research peptide market).
- U.S. Food and Drug Administration. "List of Bulk Drug Substances That May Not Be Used in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act." Federal Register notice, 2023.
- World Anti-Doping Agency. "2024 Prohibited List." WADA, 2024. (TB-500 and GH secretagogue status)
- Egrifta (tesamorelin) prescribing information. Theratechnologies Inc. Current label.